A meta-analysis of 87 trials found sitagliptin 100 mg/day and linagliptin 5 mg/day equally effective for type 2 diabetes, both reducing hemoglobin A1c by approximately 0.6% compared to placebo with similar safety profiles.
- Both drugs reduced blood sugar markers significantly compared to placebo
- No meaningful differences in effectiveness or safety between the two medications
- Neither drug increased risk of adverse events compared to placebo
How this compares to prior research
Sitagliptin and linagliptin belong to a class of diabetes medications called DPP-4 inhibitors that help control blood sugar. While both drugs have been individually studied and approved for type 2 diabetes treatment, direct comparisons of their relative effectiveness and safety have been limited. This meta-analysis pooled data from 87 randomized trials to provide the most comprehensive comparison to date.
Diabetes prevalence among adults globally, 1980–1989
Key findings
- Sitagliptin 100 mg/day reduced hemoglobin A1c by 0.64% and linagliptin 5 mg/day by 0.59% compared to placebo
- Sitagliptin lowered fasting plasma glucose by 15.16 mg/dL and linagliptin by 13.88 mg/dL versus placebo
- No significant differences in efficacy or most safety outcomes were found between sitagliptin and linagliptin
What this means in practice
- Ask your doctor whether sitagliptin or linagliptin is appropriate for your type 2 diabetes management plan
- Consider that both medications offer similar blood sugar control benefits with comparable safety profiles
- If cost or availability differs between these drugs, know that effectiveness is equivalent at standard doses
Frequently asked questions
Are sitagliptin and linagliptin equally effective for type 2 diabetes?
Yes, this analysis of 87 studies found no significant differences in blood sugar control between sitagliptin 100 mg/day and linagliptin 5 mg/day.
Do these medications cause more side effects than placebo?
No, neither sitagliptin nor linagliptin showed a significant increase in adverse events compared to placebo in this meta-analysis.
How much do these drugs lower blood sugar levels?
Both medications reduced hemoglobin A1c by approximately 0.6% and fasting blood glucose by 14-15 mg/dL compared to placebo.
Key terms explained
Hemoglobin A1c
A blood test measuring average blood sugar levels over the past 2-3 months, expressed as a percentage
Fasting plasma glucose
Blood sugar level measured after not eating for at least 8 hours, typically checked in the morning
Bayesian network meta-analysis
A statistical method that combines data from multiple studies to compare three or more treatments simultaneously
Source: Comparison and Evaluation of Efficacy and Safety of Sitagliptin and Linagliptin in Adults With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis. · DOI: doi: 10.1111/jebm.70128